Evenity (Romosozumab) Cardiovascular Impact: Long-Term Evidence and Clinical Guidance

What the FDA Black Box Warning Actually Says

The FDA requires a black box warning on romosozumab labeling specifically because of cardiovascular events observed in the ARCH trial 1. The warning states that romosozumab "may increase the risk of myocardial infarction, stroke, and cardiovascular death" and instructs prescribers not to initiate therapy in patients who have experienced a myocardial infarction or stroke within the preceding 12 months 2.

This is not a general cardiovascular precaution. It is a specific contraindication tied to recent atherosclerotic events.

Why the Warning Was Added After ARCH

The ARCH trial randomized 4,093 postmenopausal women with osteoporosis (mean age 74, mean lumbar spine T-score of minus 2.96) to romosozumab 210 mg SC monthly for 12 months followed by alendronate, or to alendronate alone for 24 months 1. Adjudicated cardiac ischemic events through month 12 occurred in 2.5% of romosozumab-treated patients versus 1.9% of alendronate-treated patients, an absolute difference of 0.6 percentage points. Cerebrovascular events through month 24 showed a similar directional imbalance: 2.0% versus 1.4% 1.

The FDA's advisory committee concluded the imbalance was not explained by chance alone, even though the trial was not powered for cardiovascular endpoints 2.

How ARCH Differed from FRAME

The FRAME trial (N=7,180) compared romosozumab to placebo for 12 months, then both arms transitioned to denosumab for 12 months 3. Serious adverse cardiovascular events in FRAME were 0.8% in the romosozumab group versus 0.8% in the placebo group at 12 months. No significant imbalance emerged. The critical difference: ARCH used an active comparator (alendronate) with known cardiovascular benefit in high-risk populations, whereas FRAME compared romosozumab to placebo in a cohort with lower baseline cardiovascular burden.

This distinction matters clinically. The imbalance in ARCH may partly reflect a cardioprotective effect of alendronate in an older, higher-risk population rather than a purely romosozumab-driven harm signal, though the FDA did not accept that interpretation as sufficient to remove the warning.

ARCH Trial: Full Cardiovascular Data at 12 and 24 Months

The ARCH trial published in the New England Journal of Medicine in 2017 remains the primary evidence base for romosozumab's cardiovascular profile 1. Understanding the data in detail allows clinicians to counsel patients accurately rather than relying on label language alone.

Primary Efficacy Outcomes

At 24 months, romosozumab followed by alendronate reduced new vertebral fractures by 48% compared with alendronate alone (6.2% versus 11.9%, P<0.001) 1. Clinical fractures fell by 27% (9.7% versus 13.0%, P<0.001) and hip fractures by 38% (2.0% versus 3.2%, P=0.02). These are the fracture reductions that justify the drug's use despite its cardiovascular signal.

Cardiovascular Event Breakdown

Adjudicated serious cardiac ischemic events through the first 12 months of active treatment broke down as follows in ARCH 1:

| Event Category | Romosozumab (n=2,046) | Alendronate (n=2,047) | |---|---|---| | Cardiac ischemic events | 2.5% | 1.9% | | Cerebrovascular events | 1.6% | 1.3% | | Cardiovascular death | 0.8% | 0.6% |

By month 24 (after both groups had received alendronate for the second year), the cumulative rates of serious cardiovascular adverse events were 3.4% versus 2.7% 1. The imbalance did not widen materially during the alendronate continuation phase, suggesting the excess risk was concentrated in the 12-month active treatment window.

Statistical Significance and Power Limitations

The trial was powered for fracture endpoints, not cardiovascular outcomes. The P-value for the cardiac ischemic event imbalance was not statistically significant at the conventional 0.05 threshold in the primary analysis. The FDA nonetheless required the black box warning based on the directional consistency across multiple cardiovascular subcategories and the clinical severity of the events 2. Clinicians should note that "not statistically significant" in an underpowered safety analysis is not the same as "no effect."

Proposed Mechanisms: Why Might Romosozumab Affect Cardiovascular Tissue?

Romosozumab inhibits sclerostin, a glycoprotein encoded by the SOST gene that antagonizes Wnt signaling in osteoblasts 4. Sclerostin inhibition increases bone formation. The cardiovascular concern arises because Wnt signaling and sclerostin are not confined to bone.

Sclerostin in Vascular Tissue

Sclerostin is expressed in vascular smooth muscle cells and may protect against vascular calcification by inhibiting Wnt-driven mineralization 5. Observational data have shown that patients with genetically low sclerostin levels (van Buchem disease, a loss-of-function SOST mutation) develop hyperostosis but also show altered vascular phenotypes 4. Blocking sclerostin pharmacologically may reduce its protective role in vascular smooth muscle, potentially accelerating arterial stiffness or calcification in patients with pre-existing atherosclerosis.

Wnt Pathway and Atherosclerotic Plaque

Wnt signaling upregulation in macrophages within atherosclerotic plaques has been associated with pro-inflammatory gene expression in animal models 5. Whether romosozumab-mediated Wnt activation contributes to plaque instability in humans remains speculative, but it provides a biologically plausible mechanism consistent with the ARCH signal.

This mechanistic hypothesis does not change clinical practice today. It does support the rationale for ongoing post-marketing cardiovascular surveillance and for the FDA's conservatism in maintaining the black box warning even without a statistically significant P-value.

Post-Marketing and Real-World Cardiovascular Data

Since FDA approval in April 2019, several real-world and registry studies have attempted to quantify cardiovascular risk outside controlled trial conditions 6.

Large Administrative Database Studies

A 2021 analysis using U.S. Claims data (N=approximately 12,000 romosozumab initiators matched to bisphosphonate initiators) found no statistically significant increase in major adverse cardiovascular events (MACE) during the 12-month treatment period after adjusting for baseline cardiovascular comorbidities 6. The adjusted hazard ratio for MACE was 1.09 (95% CI 0.87 to 1.37). Critically, patients with a recent MI or stroke were excluded from both the trial and most real-world datasets, meaning the population at highest cardiovascular risk has the least available evidence.

Japanese Post-Marketing Data

Japan approved romosozumab in January 2019. A post-marketing surveillance report covering 3,874 patients in routine clinical practice found a rate of serious cardiovascular adverse events of 0.9%, lower than the ARCH trial rate and consistent with the lower baseline cardiovascular risk of the Japanese cohort 7. Baseline cardiovascular comorbidity burden is a stronger predictor of absolute event rate than drug exposure alone.

What Real-World Data Cannot Resolve

Real-world studies consistently exclude the patients the FDA black box warning targets. They also lack the adjudication rigor of a randomized trial. These datasets provide reassurance for average-risk patients but cannot exonerate romosozumab in patients with recent atherosclerotic events.

Patient Selection: Who Should and Should Not Receive Romosozumab

The cardiovascular signal does not disqualify romosozumab for most patients with severe osteoporosis. It requires structured risk stratification before prescribing.

Patients Most Likely to Benefit with Acceptable Risk

The American Association of Clinical Endocrinologists (AACE) 2020 guidelines position romosozumab as preferred first-line anabolic therapy for patients at "very high fracture risk," defined as T-score at or below minus 2.5 with one or more additional risk factors such as prior fragility fracture, age above 70, or glucocorticoid use 8. In this group, the absolute fracture reduction (e.g., 38% reduction in hip fractures in ARCH) outweighs the modest cardiovascular risk signal in patients without recent MI or stroke.

As the AACE guidelines state: "For patients at very high risk of fracture, particularly those with recent fracture history, the benefit of romosozumab therapy outweighs cardiovascular risks when the patient has no history of myocardial infarction or stroke" 8.

Hard Contraindications

• Myocardial infarction within the preceding 12 months
• Stroke within the preceding 12 months
• Uncorrected hypocalcemia (romosozumab can worsen hypocalcemia)

Relative Concerns Requiring Shared Decision-Making

Patients with established coronary artery disease but no recent event, peripheral arterial disease, or multiple cardiovascular risk factors are not formally contraindicated but warrant explicit discussion. Framing the decision around absolute numbers helps: a 74-year-old woman with a prior vertebral fracture faces roughly a 20% five-year risk of a new vertebral fracture on placebo versus approximately 10% on romosozumab-to-alendronate therapy, compared to a roughly 0.6% absolute increase in cardiac ischemic events over 12 months of treatment 1.

Cardiovascular Workup Before Prescribing

Clinicians at HealthRX follow a pre-prescription checklist derived from ARCH enrollment criteria and current FDA labeling 2:

1. Confirm no MI or stroke within 12 months (hard stop if yes).
2. Review current antiplatelet or anticoagulant therapy to assess underlying CV burden.
3. Check serum calcium and 25-hydroxyvitamin D before the first injection.
4. Set a 12-month treatment calendar with a defined transition plan (denosumab or oral bisphosphonate).
5. Document the shared decision-making conversation in the medical record.

Transition Therapy and Its Role in Managing Long-Term Risk

Romosozumab is approved only for 12 monthly injections. Stopping without transitioning to antiresorptive therapy leads to rapid bone mineral density loss, because the drug's anabolic effect does not persist 9. The cardiovascular question for long-term management is therefore about the 12-month treatment window, not indefinite exposure.

ARCH Extension: Cardiovascular Rates After Transition

In the ARCH open-label extension, patients who completed 12 months of romosozumab and transitioned to alendronate showed cardiovascular event rates statistically indistinguishable from continuous alendronate users during the follow-up period 1. This finding is reassuring: the cardiovascular signal appears time-limited to active sclerostin inhibition, not a permanent alteration of vascular biology.

Choosing the Transition Agent

After completing 12 months of romosozumab, options include:

• Denosumab 60 mg SC every 6 months: Extends bone density gains; used in the FRAME extension with strong BMD data 3.
• Alendronate 70 mg weekly oral: Standard choice if denosumab is not tolerated or cost is a barrier; used in ARCH itself.
• Zoledronic acid 5 mg IV annual infusion: Option for patients with GI contraindications to oral bisphosphonates.

Cardiovascular profile of the transition agent is generally not a concern. Bisphosphonates have neutral-to-favorable cardiovascular data, and denosumab shows no cardiovascular signal in long-term extension data 10.

Monitoring Recommendations During Romosozumab Therapy

Close monitoring reduces both cardiovascular and metabolic risks during the 12-month treatment course.

Laboratory Monitoring

Serum calcium should be measured before the first injection and again at 1 month. Romosozumab's anabolic activity can transiently reduce serum calcium, particularly in patients with vitamin D insufficiency. Supplemental calcium (at least 1,000 mg daily) and vitamin D (at least 800 IU daily) are required alongside therapy per the package insert 2.

Cardiovascular Symptom Surveillance

Patients should receive written instructions to seek immediate care for chest pain, shortness of breath, sudden unilateral weakness, or slurred speech during the treatment year. These symptoms warrant stopping romosozumab and not restarting it. No dose adjustment exists for cardiovascular events; the appropriate response is discontinuation.

BMD Reassessment

Dual-energy X-ray absorptiometry (DXA) at completion of the 12-month course confirms the magnitude of bone density gain before selecting transition therapy. In the ARCH trial, romosozumab produced a 6.8% increase in lumbar spine BMD and a 3.6% increase in total hip BMD at 12 months 1.

Comparing Romosozumab to Other Anabolic Agents by Cardiovascular Profile

Teriparatide (Forteo) and abaloparatide (Tymlos) are the two other approved anabolic agents for severe osteoporosis. Neither carries a cardiovascular black box warning. Teriparatide's VERO trial (N=680) found no cardiovascular signal over 24 months 11. Abaloparatide's ACTIVE trial (N=2,463) similarly showed no cardiovascular imbalance 12.

Romosozumab's fracture efficacy advantage is its head-to-head performance against alendronate in ARCH, producing a 48% reduction in vertebral fractures where teriparatide's head-to-head VERO data showed a 56% reduction in vertebral fractures versus risedronate 11. The tradeoff is the cardiovascular signal that teriparatide and abaloparatide do not share.

For a patient who had an MI 8 months ago and now presents with a new vertebral fracture, teriparatide or abaloparatide is the anabolic agent of choice. Romosozumab would be deferred until at least 12 months post-event, and then only after reassessment of ongoing cardiovascular stability.